

## List of amendments to chapter 11-850, HAR, effective November 17, 2022

- 1) Conform regulations with statutory changes made by 2022 SLH Act 309 [§§6, 7, 46]
  - a) Maximum number of allowable production centers and retail dispensing locations per license and cannabis plants per production center
  - b) Allowance for transportation of cannabis and manufactured cannabis products from a dispensary to another island or county for laboratory testing only if there is no certified laboratory located on the island or in the county where the dispensary is located
- 2) Add a dispensary license renewal fee structure differentiated by number of production centers, maximum number of plants, type of manufacturing activity, number of retail dispensing locations, county, and market share [§28]
- 3) Add delta-8-tetrahydrocannabinol to the definition of total tetrahydrocannabinol [§2]
- 4) Revise laboratory testing requirements [§135]
  - a) Add delta-9-tetrahydrocannabinolic acid and delta-8-tetrahydrocannabinol
  - b) Add the following contaminants with testing limits
    - i) Solvents: 1,1-dichloroethene, 1,1,1-trichloroethane, 1,2-dichloroethane, acetone, acetonitrile, carbon tetrachloride, chloroform, ethyl acetate, ethyl ether, isopropyl alcohol, methanol, methylene chloride, propane, trichloroethylene
    - ii) *Aspergillus terreus*
  - c) Replace “(A) Water activity (aw), which shall not exceed 0.65; or (B) Moisture content, which shall not exceed fifteen per cent” with “water activity (aw), which shall not exceed 0.65”
  - d) Add water activity limit for kief and hashish
- 5) Add batch sampling and testing requirements for quality control and procedures for batches failing testing standards [§78, 129, 131, 134, 135(h)(1), (i)]
  - a) Add sampling requirements: maximum batch size, multi-incremental sampling, minimum number of increments by batch size, minimum sample size
  - b) Clarify requirements for validation studies and proficiency testing
  - c) Add documentation relating to validity of laboratory testing of individual products
  - d) Expand possibilities and codify procedures for remediation of batches failing testing standards
  - e) Clarify timeline for destruction of batches failing testing standards
  - f) Reduce reserve sample holding time
- 6) Add and clarify product safety and labeling requirements [§§2, 72(d), 143, 145(d)]
  - a) Clarify banned ingredients by replacing “cannabinoids created through isomerization...” with “artificially derived cannabinoids” and defining the new term
  - b) Add delta-8-THC to the definition of total THC, which also means delta-8-THC is included in dosage limits on total THC and labeling for total THC content

- c) Add total package content and per serving content labeling for delta-9-THCA and delta-8-THC
  - d) Ban health or benefit claims that are unsubstantiated, false, or misleading in any particular by a dispensary or on product packaging
  - e) Require accuracy in cannabinoid content labeling
- 7) Update and clarify laboratory certification requirements and procedures [§§132, 133]
- a) Add language on scope of accreditation and demonstration of capacity and proficiency to test cannabis and medical cannabis products
  - b) Clarify requirement to submit annual proficiency tests with application for certification/re-certification
  - c) Reduce requirement for department to conduct on-site evaluation of a laboratory seeking certification: required for initial certification and full certification after a period of provisional certification, at the discretion of the department for renewal of certification
- 8) Miscellaneous clarifications
- a) Relationships between dispensaries and physician or advanced practice registered nurse who provides written certification [§31(c)]
  - b) Procedures for appeals [§§24(c), 136]
  - c) Procedure for notifying the department of a security breach [§51(b)]

Conforming changes and organizational changes are also made.